HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by McFarland, L. V Search for Related Content PubMed PubMed Citation Articles by McFarland, L. V Agricola Articles by McFarland, L. V

Alternative treatments for Clostridium difficile disease: what really works?

University of Washington, HSR&D, 1100 Olive Street, #1400, Seattle, WA 98101, USA

Correspondence Lynne V. McFarland lvmcfarl{at}u.washington.edu

Vancomycin and metronidazole have been used for treating Clostridium difficile-associated disease (CDAD) for the past 25 years, but approximately 20 % of patients develop recurrent disease. The increasing incidence of nosocomial outbreaks, cases of recurrent CDAD and other complications (toxic megacolon, ileus, sepsis) has fuelled the search for different types of treatments. As the understanding of the pathogenesis of this disease has matured, newer treatment strategies that take advantage of these mechanisms have been developed. This review will describe such treatments and examine the evidence for each strategy.

This article has been cited by other articles:

				R. D. Sleator and C. Hill Designer probiotics: a potential therapeutic for Clostridium difficile? J. Med. Microbiol., June 1, 2008; 57(6): 793 - 794. [Full Text] [PDF]

				M. E. Pelleschi Clostridium difficile-Associated Disease: Diagnosis, Prevention, Treatment, and Nursing Care Crit. Care Nurse, February 1, 2008; 28(1): 27 - 35. [Full Text] [PDF]

				D. B. Blossom, F. M.T. Lewis, and L. C. McDonald The Changing Spectrum of Clostridium Difficile Associated Disease: Implications for Dentistry J Am Dent Assoc, January 1, 2008; 139(1): 42 - 47. [Abstract] [Full Text] [PDF]

				M. C. Rea, E. Clayton, P. M. O'Connor, F. Shanahan, B. Kiely, R. P. Ross, and C. Hill Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains J. Med. Microbiol., July 1, 2007; 56(7): 940 - 946. [Abstract] [Full Text] [PDF]

				M. Segarra-Newnham Probiotics for Clostridium difficile-Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii Ann. Pharmacother., July 1, 2007; 41(7): 1212 - 1221. [Abstract] [Full Text] [PDF]

				S. C Numan, P. Veldkamp, E. J Kuijper, R. J van den Berg, and J. T van Dissel Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses Gut, June 1, 2007; 56(6): 888 - 889. [Full Text] [PDF]

				N. Sadeghifard, V. Gurtler, M. Beer, and R. J. Seviour The Mosaic Nature of Intergenic 16S-23S rRNA Spacer Regions Suggests rRNA Operon Copy Number Variation in Clostridium difficile Strains Appl. Envir. Microbiol., November 1, 2006; 72(11): 7311 - 7323. [Abstract] [Full Text] [PDF]

				J. G. S. Ho, A. Greco, M. Rupnik, and K. K.-S. Ng Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A PNAS, December 20, 2005; 102(51): 18373 - 18378. [Abstract] [Full Text] [PDF]

				S. J Lawrence, J. R Korzenik, and L. M Mundy Probiotics for recurrent Clostridium difficile disease J. Med. Microbiol., September 1, 2005; 54(9): 905 - 906. [Full Text] [PDF]

				I. R Poxton Clostridium difficile J. Med. Microbiol., February 1, 2005; 54(2): 97 - 100. [Full Text] [PDF]